Elias Jabbour, MD

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

Shared insight on recently updated data in acute myeloid leukemia following the ASH 2022 annual meeting.

Experts in hematologic oncology review and analyze updated data in chronic myeloid leukemia from ASH 2022.

Following the ASH 2022 Annual Meeting, hematologic oncology experts discuss updated data in acute lymphocytic leukemia.

Elias Jabbour, MD, discusses the evaluation of olverembatinib in patients with ponatinib-resistant chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Elias Jabbour, MD, discusses the importance of testing for minimal residual disease when determining optimal treatment strategies for patients with B-cell acute lymphoblastic leukemia.

Shared insight from expert oncologists on key clinical trial data in lymphomas from the ASCO 2022 and EHA 2022 Annual Meetings.

Expert oncologist perspectives on key clinical trial data in acute lymphocytic leukemia from the ASCO 2022 and EHA 2022 Annual Meetings.

Closing thoughts on advances and future perspectives in the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Expectations regarding where novel therapies such as CAR T-cell therapies will fit into B-cell acute lymphoblastic leukemia treatment algorithms as data from clinical trials continue to evolve.

Discussion on the role of transplantation in the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

The significance of having novel therapies and molecular tests available to help guide treatment decisions for patients with B-cell acute lymphoblastic leukemia, and recommendations on how to increase the uptake of MRD testing into routine clinical practice.

When to test for measurable residual disease in B-cell acute lymphoblastic leukemia, and what to keep in mind when selecting a testing method to help assess MRD.

Emerging therapies in the clinical pipeline for relapsed/refractory B-cell acute lymphoblastic leukemia, as presented at ASH 2021.

An overview of adverse events commonly associated with CAR T-cell therapies in relapsed/refractory B-cell acute lymphoblastic leukemia.

Recommendations for sequencing CAR T-cell therapies and other key therapies in patients with B-cell acute lymphoblastic leukemia.

Implications of the ZUMA-3 clinical trial of anti-CD19 CAR T-cell therapy for adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

The treatment approaches available for patients with B-cell acute lymphoblastic leukemia, and reactions to the availability of novel CAR T therapies for relapsed/refractory disease.

Background information regarding the manifestation and prognosis of relapsed/refractory B-cell acute lymphoblastic leukemia.

Elias Jabbour, MD, discusses the rationale to evaluate KO-539 in relapsed/refractory acute myeloid leukemia.

Elias Jabbour, MD, discusses selecting ponatinib after failure of a second-generation TKI therapy in chronic myeloid leukemia.

Elias Jabbour, MD, discusses data with asciminib in patients with chronic-phase chronic myeloid leukemia.

Elias Jabbour, MD, an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses recent advances in the treatment of patients with acute lymphoblastic leukemia.

Elias Jabbour, MD, an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses blinatumomab (Blincyto) in acute lymphoblastic leukemia.

Elias Jabbour, MD, an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses recent treatment advances and emerging subsets in acute lymphoblastic leukemia (ALL).

​Elias Jabbour, MD, associate professor, department of leukemia, division of cancer medicine, the University of Texas MD Anderson Cancer Center, discusses blinatumomab (Blincyto) for acute lymphocytic leukemia (ALL).

Elias Jabbour, MD, Assistant Professor, Dept. of Leukemia, The University of Texas MD Anderson Cancer Center, discusses front-line treatments for CML, at the 2010 ASCO Annual Meeting.

Elias Jabbour, MD, Assistant Professor, Dept. of Leukemia, The University of Texas MD Anderson Cancer Center, on second-generation TKIs for patients with CML, a cancer that starts inside bone marrow.